Gapping down
In reaction to disappointing earnings/guidance: MCRB -76.9%, SFS -21.8%,EHTH -14.7%, MDCA -12.2%, CAA -10.8%, FTNT -10.7%, HIG -10.7%, PSO-10.2%, CYBE -10.1%, ACRX -9.1%, WYNN -8.8%, SRCL -8.4%, (also discloses that various prior financial statements should no longer be relied upon due to errors in the timing of recognition of certain loss reserves ), CI -8.1%,RCKY -7.3%, LPNT -6.4%, EXPE -6.2%, EXPE -6.2%, ERJ -5.7%, EYES -5.3%, (also to distribute the Argus II Retinal Prosthesis System in Taiwan through exclusive agreement with Orient Europharma and in Iran through Arshia Gostar Darman), QSII -5.1%, WDC -5%, ESS -4.8%, BIDU -3.6%, EMN -3.4%,DRQ -2.9%, SNY -2.7%, ISIL -2.6%, XOM -2.6%, COLM -2.5%, MSTR -2.2%,INVN -2.2%, SAIA -1.9%, SYNA -1.8%, WETF -1.8%, FNFG -1.8%, E -1.8%, UPS-1.7%, DLR -1.6%, AUY -1.5%, (also announces sale of Mercedes mine in Mexico ), CVX -1.5%, LYB -1.3%, .
Select metals/mining stocks trading lower: RIO -1.8%, BHP -1.8%, VALE-1.7%, FCX -1.6%
Other news:
In reaction to disappointing earnings/guidance: MCRB -76.9%, SFS -21.8%,EHTH -14.7%, MDCA -12.2%, CAA -10.8%, FTNT -10.7%, HIG -10.7%, PSO-10.2%, CYBE -10.1%, ACRX -9.1%, WYNN -8.8%, SRCL -8.4%, (also discloses that various prior financial statements should no longer be relied upon due to errors in the timing of recognition of certain loss reserves ), CI -8.1%,RCKY -7.3%, LPNT -6.4%, EXPE -6.2%, EXPE -6.2%, ERJ -5.7%, EYES -5.3%, (also to distribute the Argus II Retinal Prosthesis System in Taiwan through exclusive agreement with Orient Europharma and in Iran through Arshia Gostar Darman), QSII -5.1%, WDC -5%, ESS -4.8%, BIDU -3.6%, EMN -3.4%,DRQ -2.9%, SNY -2.7%, ISIL -2.6%, XOM -2.6%, COLM -2.5%, MSTR -2.2%,INVN -2.2%, SAIA -1.9%, SYNA -1.8%, WETF -1.8%, FNFG -1.8%, E -1.8%, UPS-1.7%, DLR -1.6%, AUY -1.5%, (also announces sale of Mercedes mine in Mexico ), CVX -1.5%, LYB -1.3%, .
Select metals/mining stocks trading lower: RIO -1.8%, BHP -1.8%, VALE-1.7%, FCX -1.6%
Other news:
- MCRB -77.4% (announces that its SER-109 Phase 2 ECOSPORT study on multiply recurrent Clostridium difficile infection did not achieve its primary endpoint)
- QTNT -20.1% (commences an underwritten public offering of its ordinary shares for an undisclosed amount ), LVS -2.9% (WYNN sympathy), MPEL -2.7% (WYNN sympathy)
- TRIP -2.1% (following EXPE earnings)
- PCLN -2% (following EXPE earnings)
- MGM -1.8% (WYNN sympathy
- JAZZ -0.9% (Jazz Pharma and Pfenex announce agreement under which Pfenex granted Jazz worldwide rights to develop and commercialize multiple early stage hematology product candidates)
Analyst comments:
- GRUB -3.6% (downgraded to Neutral from Buy at Monness Crespi & Hardt)
- DE -1.6% (downgraded to Neutral from Buy at UBS)
- TAP 1.3% (upgraded to Buy from Neutral at Citigroup)
- BTI -0.7% (downgraded to Hold from Buy at Societe Generale)
- F -0.6% (downgraded to Neutral from Buy at Goldman)